[18F]FDG PET 图像中有前景的候选预后生物标志物:在非小细胞肺癌患者独立队列中的评估
本研究在 99 例非小细胞肺癌(NSCLC)患者中评估 NHOC 与 NHOP 对成像参数的稳健性,并在 244 例晚期 NSCLC 患者中分析其预后价值。结果显示 NHOC 与 NHOP 较 SUV 对滤波与重采样更稳健,且与 SUV 等影像组学特征相关性弱;在免疫治疗队列中 NHOC 可区分总生存(P<0.01),NHOP 在靶向治疗(P=0.02)与免疫治疗(P<0.01)亚组中可分层总生存。
要点
- NHOC 与 NHOP 对高斯后滤波和重采样较 SUV 更稳健。
- NHOC 与 NHOP 之间、与其它影像组学特征之间相关性弱。
- NHOC 在免疫治疗队列中可区分总生存(P<0.01)。
核心结论
- 作者认为,即使在晚期 NSCLC 患者中,原发肿瘤的 NHOC 与 NHOP 特征具有预后潜力,且对成像方案参数稳健并与其他影像组学特征互补。
- 作者指出这些特征现已在 LIFEx 软件中可用,供他人独立测试。
研究设计与样本
- 回顾性研究,分析基线 [18F]FDG PET 扫描。
- 队列 1 纳入 99 例无治疗相关入组标准的 NSCLC 患者,用于稳健性研究。
- 队列 2 纳入 244 例 NSCLC 患者进行生存分析,其中靶向治疗 93 例、免疫治疗 63 例、免疫化疗 88 例。
- 98% 患者有转移,影像组学特征(包括 SUV)仅从原发肿瘤提取。
- NHOC 与 NHOP 采用两种方法计算:SUVmax 或 SUVpeak 定位到肿瘤质心或周边的归一化距离。
主要发现
- 队列 1 中,NHOC 与 NHOP 特征对图像滤波和重采样较 SUV 更稳健。
- NHOC 与 NHOP 之间相关性弱(r≤0.45),NHOC 或 NHOP 与任何其他影像组学特征之间相关性弱(r≤0.60)。
- 队列 2 中,总生存短的患者相比总生存长的患者表现出更高的 NHOC 和更低的 NHOP。
- 免疫治疗患者中 NHOC 显著区分两种生存曲线(log-rank 检验,P<0.01)。
- 靶向治疗(P=0.02)和免疫治疗(P<0.01)亚队列中 NHOP 可对患者总生存进行分层。
关键数值与推荐
- Bland-Altman 分析比较有无高斯后滤波的 PET 图像以评估空间分辨率影响,比较两种体素大小以评估图像采样影响。
- Spearman 相关系数(r)用于研究 NHOC 和 NHOP 与其他特征的相关性。
- Kaplan-Meier 法用于估计 NHOC 和 NHOP 预测总生存(OS)的能力。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The normalized distances from the hot spot of radiotracer uptake (SUVmax) to the tumor centroid (NHOC) and to the tumor perimeter (NHOP) have recently been suggested as novel PET features reflecting tumor aggressiveness. These biomarkers characterizing the shift of SUVmax toward the lesion edge during tumor progression have been shown to be prognostic factors in breast and non-small cell lung cancer (NSCLC) patients. We assessed the impact of imaging parameters on NHOC and NHOP, their complementarity to conventional PET features, and their prognostic value for advanced-NSCLC patients. Methods: This retrospective study investigated baseline [18F]FDG PET scans: cohort 1 included 99 NSCLC patients with no treatment-related inclusion criteria (robustness study); cohort 2 included 244 NSCLC patients (survival analysis) treated with targeted therapy (93), immunotherapy (63), or immunochemotherapy (88). Although 98% of patients had metastases, radiomic features including SUVs were extracted from the primary tumor only. NHOCs and NHOPs were computed using 2 approaches: the normalized distance from the localization of SUVmax or SUVpeak to the tumor centroid or perimeter. Bland-Altman analyses were performed to investigate the impact of both spatial resolution (comparing PET images with and without gaussian postfiltering) and image sampling (comparing 2 voxel sizes) on feature values. The correlation of NHOCs and NHOPs with other features was studied using Spearman correlation coefficients (r). The ability of NHOCs and NHOPs to predict overall survival (OS) was estimated using the Kaplan-Meier method. Results: In cohort 1, NHOC and NHOP features were more robust to image filtering and to resampling than were SUVs. The correlations were weak between NHOCs and NHOPs (r ≤ 0.45) and between NHOCs or NHOPs and any other radiomic features (r ≤ 0.60). In cohort 2, the patients with short OS demonstrated higher NHOCs and lower NHOPs than those with long OS. NHOCs significantly distinguished 2 survival profiles in patients treated with immunotherapy (log-rank test, P < 0.01), whereas NHOPs stratified patients regarding OS in the targeted therapy (P = 0.02) and immunotherapy (P < 0.01) subcohorts. Conclusion: Our findings suggest that even in advanced NSCLC patients, NHOC and NHOP features pertaining to the primary tumor have prognostic potential. Moreover, these features appeared to be robust with respect to imaging protocol parameters and complementary to other radiomic features and are now available in LIFEx software to be independently tested by others.
引用
- Hovhannisyan-Baghdasarian N, Luporsi M, Captier N, et al. Promising Candidate Prognostic Biomarkers in [18F]FDG PET Images: Evaluation in Independent Cohorts of Non-Small Cell Lung Cancer Patients. J Nucl Med. 2024. PMID: 38453361. doi:10.2967/jnumed.123.266331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。